Many holders, investors are over reacting to the latest Announcement by DR T,
the way I read it is a pretty simple message that the FDA review is underway for three orphan drug applications and if granted will boost price and value of NEU assets. Torreya will continue to evaluate potential corporate transactions given the importance of the near term milestones. Qtr 4 of 2019 is not far away and FDA review should be finalised in October as application for orphan designation was submitted end July and generally take 3 months to complete.
Ann: Neuren approaching key milestones in Q4 2019, page-38
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |